LL-37: A Comprehensive Review of Its Biological Functions, Mechanisms, and Therapeutic Potential of Cathelicidin

Rizwana Sheik Kasim[1], Kavitha Rajendran[2]
[1]*Department of Pharmaceutics, SRM College of Pharmacy, Kattankulathur, Tamil Nadu, India*
[2]*Department of Pharmacy, SRM College of Pharmacy, SRM Institute of Science and Technology, Kattankulathur-603203, Tamil Nadu*

Abstract- LL-37, a key antimicrobial peptide derived from the precursor hCAP-18, is an essential component of the human innate immune system. As the only member of the cathelicidin family in humans, LL-37 plays a multifaceted role in host defense, antimicrobial activity, immunomodulation, and wound healing. Its broad-spectrum antimicrobial effects, coupled with its capacity to influence immune responses and tissue regeneration, highlight its therapeutic potential. This review will provide an in-depth analysis of LL-37's structure, biological functions, mechanisms of action, and its emerging therapeutic applications in clinical settings. Furthermore, we will discuss ongoing research efforts aimed at harnessing LL-37 for novel therapeutic strategies, as well as challenges related to its clinical use.

Keywords: Antimicrobial peptides, Cathelicidin, hCAP-18, Immune modulation, LL-37, Tissue regeneration, Wound healing

1. INTRODUCTION

Peptides are short chains of amino acids linked together by peptide bonds. Amino acids are organic compounds that combine in various sequences to form proteins. In peptides, the chain length can range from just two amino acids (known as dipeptides) to around 50 amino acids (longer chains are generally considered proteins). While proteins can be made up of hundreds or even thousands of amino acids, peptides are smaller, simpler versions.

1.1. STRUCTURE OF PEPTIDES

- Amino Acids: The basic units that make up peptides are amino acids, which contain both an amino group (-NH2) and a carboxyl group (-COOH).
- Peptide Bonds: When two amino acids join, a peptide bond forms between the amino group of one amino acid and the carboxyl group of another. This bond results in the release of a molecule of water (H2O), a process known as condensation or dehydration. Sequence: The sequence of amino acids determines the function and properties of the peptide. The sequence is read from the N-terminus (the end with the carboxyl group).

TYPES OF PEPTIDES

1.Oligopeptides: Peptides with a small number of amino acids (typically 2 to 20).

2.Polypeptides: Longer chains of amino acids, typically consisting of more than 20 but fewer than 50 amino acids.

3.Bioactive Peptides: These are peptides that have a biological effect on the body and are involved in signaling and regulating various physiological functions.

4.Peptide Hormones: Short chains of amino acids that function as messengers, transmitting signals between cells and organs to regulate bodily processes.

1.2 IMPORTANCE OF PEPTIDES

Peptides have diverse biological roles and are crucial in many bodily functions. Their importance spans several areas, including:

1.3. CELL SIGNALING & COMMUNICATION

Peptides play a significant role in cell signaling, which allows cells to communicate with each other and with the environment. This communication is vital for processes such as growth, immune responses, and the regulation of metabolism.

1.4. HORMONAL FUNCTIONS

Peptide hormones are essential for regulating various bodily functions. Examples include:

- Insulin: Regulates blood sugar levels by promoting the uptake of glucose into cells.
- Oxytocin: Often referred to as the "love hormone," it regulates childbirth and lactation, as well as bonding and social behaviors.
- Growth Hormone: Stimulates growth, cell reproduction, and regeneration.

2.1. IMMUNE SYSTEM REGULATION

Peptides are involved in immune responses. For example:

- Defensins: Antimicrobial peptides that help fight infections.
- Cytokines: Peptides that regulate immune cell activity and inflammation.
- Antimicrobial peptides: Serve as a first line of defense against pathogens.

2.2. NEUROTRANSMISSION

Peptides also function as neurotransmitters or neuromodulators, transmitting signals between nerve cells (neurons) and influencing brain activity. Examples include:

- Endorphins: Peptides that act as natural painkillers and improve mood.
- Substance P: Involved in the transmission of pain and inflammatory responses.
- Vasopressin: Involved in water retention by the kidneys and regulating blood pressure.

2.3. MUSCLE GROWTH & REPAIR

Peptides like creatine and BPC-157 (Body Protective Compound-157) are known to stimulate muscle growth, repair, and recovery, making them popular in bodybuilding and fitness circles.

2.4. SKIN HEALTH AND ANTI-AGING

Certain peptides have been shown to stimulate collagen production and promote skin regeneration, helping with anti-aging effects. For example:

- Collagen peptides: Aid in maintaining skin elasticity and hydration.
- Signal peptides: Promote skin healing and rejuvenation.

They are often included in cosmetic products for reducing wrinkles and improving skin tone.

2.5. THERAPEUTIC USES

- Peptide-based drugs: Many peptides are used or being investigated for the treatment of various diseases, such as cancer, diabetes, and cardiovascular diseases. GLP-1 agonists (like semaglutide): Used for type 2 diabetes treatment.
- Vasopressin analogs: Used to treat conditions like diabetes insipidus.
- Cancer therapies: Peptides can be used to target specific cancer cells without affecting surrounding healthy cells, offering a potential for targeted cancer treatments.

3. PEPTIDES IN MEDICINE AND RESEARCH

3.1. DRUG DEVELOPMENT

Peptides are used in the creation of biopharmaceuticals. These can serve as drugs for a wide range of conditions, especially those where traditional small molecule drugs might not be as effective.

Peptide-based drugs are generally more specific and less toxic than conventional drugs.

3.2. VACCINE DEVELOPMENT

Peptide vaccines are under research for treating infectious diseases and cancers. They work by introducing synthetic peptides that mimic parts of viruses or cancer cells, training the immune system to recognize and attack these invaders.

3.3. PEPTIDE THERAPIES

Peptide hormone therapy: This includes insulin for diabetes, oxytocin for labor induction, and others like growth hormone for growth deficiencies.

Antimicrobial peptides (AMPs): These are studied for their potential as alternative therapies for drug-resistant infections.

3.4. COSMETICS & ANTI-AGING TREATMENTS

As mentioned, peptides are commonly used in cosmetic products, particularly in anti-aging treatments. They stimulate collagen production, improve skin texture, and reduce wrinkles.

3.5. SOURCES OF PEPTIDES

- Dietary Peptides: Peptides can be obtained from food sources like meat, dairy products, eggs, legumes, and fish. These dietary peptides can have bioactive effects, influencing health and wellness.
- Synthetic Peptides: In laboratories, peptides can be artificially synthesized for use in medicine, cosmetics, and research.

3.6. ANTIMICROBIAL PEPTIDE

The immune system relies on a variety of defense mechanisms to protect the body from infections, with antimicrobial peptides (AMPs) playing a crucial role in the first line of defense. LL-37, a cathelicidin-type AMP, is central to innate immunity in humans, with a broad spectrum of antimicrobial properties and additional functions in immune modulation, wound healing, and tissue repair. Unlike many other AMPs, LL-37 is unique in its dual ability to directly fight pathogens and regulate immune responses, making it an attractive candidate for therapeutic exploration.

In this review, we aim to provide a comprehensive overview of LL-37, including its origin, biological significance, mechanisms of action, and potential clinical applications. Understanding the multifaceted roles of LL-37 is crucial for its incorporation into future therapeutic strategies aimed at combating infections, autoimmune diseases, and promoting tissue regeneration.

AMPs display great variations in amino acid sequence and structure but share some features; most AMPs are small molecules usually composed of 12 to 50 amino acids—rich in arginine and lysine residues, which confer a general positive charge, making them cationic. These chemical properties allow these molecules to easily disrupt and/or permeate the membrane of microorganisms, which have a negative charge, resulting in their death. Besides interacting with charged membranes, AMPs display multiple antimicrobial and immunomodulatory properties. Many peptides can be translocated through membranes and bind to intracellular targets, modulating gene expression, protein synthesis and organelle function; others can bind to receptors in immune cells, mediating microbicidal, immunomodulatory or apoptotic responses. Cathelicidins represent a class of cationic antimicrobial peptides distributed across various organisms, including mammals, birds, reptiles, amphibians, and fish. Within mammals, the cathelicidin family encompasses approximately 30 peptides. The number of functional genes encoding cathelicidins varies among species, with humans, mice, rats, and dogs possessing a single encoded gene, whereas pigs, cows, rabbits, horses, goats, and sheep harbor up to 11 distinct cathelicidin genes. The genetic structure responsible for cathelicidin synthesis comprises four exons. Notably, exon 1 encodes a sequence spanning 29 to 30 amino acids, while exons 2 and 3 collectively encode a conserved domain, known as cathelin, consisting of 99 to 114 amino acids. This structural arrangement gives rise to the name "cathelicidins" Finally, exon 4 encodes the mature peptide, ranging from 12 to 100 amino acids, which exhibits antimicrobial and immunomodulatory activities.



FIGURE 1
Genetic organization of cathelicidins. Schematic representation of the gene orientation of cathelicidins, with the respective cleavage site to produce the mature peptide (upper part), and the main types of cathelicidin structures (bottom part).

Fig 1: Genetic organization of cathelicidin

4. STRUCTURE AND DERIVATION OF LL-37

LL-37 is the active form of hCAP-18, a larger precursor protein. The following sections describe the process of LL-37's formation and its structural features, LL-37 is a human antimicrobial peptide that belongs to the cathelicidin family. It plays an essential role in the body's immune defense, with significant functions in antimicrobial activity, inflammation regulation, and wound healing:

- Amino Acid Sequence:
  LL-37 is a peptide consisting of 37 amino acids. Its sequence is as follows:
  The name LL-37 derives from the first two amino acids (Leucine-Leucine, or "LL") in the peptide sequence, followed by the length of the peptide chain, which is 37 amino acids in total.
- Charge:LL-37 is a cationic (positively charged) peptide, which means it carries a positive charge at physiological pH. This characteristic allows it to interact with negatively charged microbial membranes, which helps it disrupt and kill various pathogens like bacteria, fungi, and viruses.
- Secondary Structure: The structure of LL-37 is amphipathic, meaning it has both hydrophobic (water-repellent) and hydrophilic (water-attracting) regions. This dual nature allows LL37 to insert itself into the lipid bilayers of microbial cell membranes, disrupting the integrity of these membranes. LL-37's secondary structure is alpha-helical, meaning that the peptide adopts a helix-like shape in its functional form. This structure is essential for its antimicrobial properties, as it enables the peptide to interact with and penetrate microbial membranes.

4.1. DERIVATION OF LL-37

LL-37 is derived from a larger precursor protein called hCAP-18 (human Cathelicidin Antimicrobial Protein-18). The process of derivation involves the cleavage of hCAP-18 into the active LL-37 peptide.

- Precursor (hCAP-18):The full-length protein hCAP-18 is produced as an inactive precursor. It contains a signal peptide and the cathelin domain, which are cleaved off to produce the active antimicrobial peptide.
- Cleavage Process: The hCAP-18 protein undergoes enzymatic processing, where the cathelin domain (the N-terminal region) is cleaved off by proteinase enzymes like elastase or cathepsin G. This cleavage process results in the formation of LL-37 at the C-terminus of the hCAP-18 precursor. The full-length hCAP-18 is about 18 kDa in size, and after cleavage, the LL-37 peptide is released as a 3.5 kDa antimicrobial peptide.
- Location: hCAP-18 is primarily produced by neutrophils, which are a type of white blood cell involved in immune responses. It is also expressed in various other cells, such as keratinocytes (skin cells), and in organs like the lungs, intestines, and mammary glands. LL-37 is produced and secreted in response to infection or injury to help the body fight pathogens and promote healing.

4.2. FUNCTIONS AND MECHANISM OF LL-37

LL-37 plays several critical roles in the body, from antimicrobial activity to immune modulation and wound healing.

4.3. MECHANISM OF ACTION OF LL-37

- LL-37 disrupts the integrity of microbial cell membranes by integrating itself into the lipid bilayer. Due to its amphipathic nature, it aligns in a way that disrupts the membrane's structural integrity, leading to leakage of cellular contents and ultimately death of the pathogen.
- LL-37 is particularly effective against Gram-positive bacteria (such as *Staphylococcus aureus*) and Gram-negative bacteria (such as *Escherichia coli*), as well as fungi and viruses. It can also disrupt biofilms, which are clusters of bacteria protected by a slimy matrix that can make infections harder to treat.

4.4. MEMBRANE DISRUPTION

The amphipathic structure of LL-37 allows it to integrate into microbial membranes, forming pores or causing membrane disruption. By disrupting the integrity of the membrane, LL-37 leads to the leakage of cellular components, causing cell death. This mechanism is effective against a wide range of pathogens, including bacteria, fungi, and some viruses.

4.5. IMMUNE CELL ACTIVATION

LL-37 binds to specific receptors on immune cells, such as formyl peptide receptors (FPRs), and P2X7 receptors, triggering intracellular signaling pathways. These interactions activate pathways that recruit additional immune cells to the site of infection and modulate the production of cytokines, thereby regulating the inflammatory response.

4.6. MODULATION OF GENE EXPRESSION

LL-37 can influence gene expression by interacting with transcription factors that control immune cell functions. This includes increasing the production of pro-inflammatory cytokines or inducing tolerance to prevent excessive inflammation, depending on the context of infection or injury.

4.7. IMMUNE MODULATION

- LL-37 does not only kill pathogens; it also modulates the immune system. It acts as a chemoattractant, drawing immune cells like neutrophils, monocytes, and macrophages to the site of infection or injury.
- LL-37 influences the production of various cytokines, which are signaling molecules that regulate inflammation and immune responses.
- It can balance the immune response, promoting an appropriate level of inflammation and preventing excessive immune activation that can lead to tissue damage or autoimmune diseases.

4.8 WOUND HEALING

- LL-37 promotes tissue repair by stimulating keratinocyte migration, cell proliferation, and collagen formation. These processes are essential for skin regeneration and wound healing.
- It also has a pro-angiogenic effect, meaning it can help in the formation of new blood vessels, which is crucial for healing wounds and restoring tissue function.

4.9 REGULATION OF INFLAMMATION

LL-37 has a dual role in inflammation:

- It can help resolve excessive inflammation and promote tissue healing by regulating pro-inflammatory cytokines.
- However, in some autoimmune conditions, like systemic lupus erythematosus (SLE), LL-37 can contribute to the amplification of inflammation if it is overexpressed, leading to tissue damage and exacerbation of the disease.

5. CATHELICIDIN FAMILY

The cathelicidin family is a group of AMPs found in various species. In humans, the family consists of a single peptide, LL-37, derived from hCAP-18. The cathelicidin family is characterized by a conserved cathelin domain, a region of about 60-70 amino acids that is responsible for the peptide's antimicrobial property



Fig 2: Cathelicidin mechanism

5.1 MECHANISM OF CATHELICIDINS

The mechanism of action of cathelicidins is multifaceted, making them essential components of the innate immune system. Their ability to:

1. Disrupt microbial membranes by forming pores, Break down biofilms,
2. Modulate immune responses to maintain balance,
3. Enhance wound healing and tissue regeneration,
4. Provide antiviral and anticancer effects,

positions them as powerful tools in the fight against infections and in promoting healing. Research into their clinical applications continues, especially in the context of antibiotic resistance, chronic wound management, and immune-related disorders.

6.DISRUPTION OF MICROBIAL MEMBRANES

The primary mechanism by which cathelicidins exert their antimicrobial activity is by directly disrupting the membranes of pathogens (bacteria, fungi, viruses). This process is highly dependent on the amphipathic (both hydrophobic and hydrophilic) nature of cathelicidins.

6.1. PROCESS OF MEMBRANE DISRUPTION

- Amphipathic Nature: Cathelicidins have both hydrophilic (water-loving) and hydrophobic (water-repellent) regions. The hydrophobic region interacts with the lipid bilayers of microbial membranes, while the hydrophilic region faces the aqueous environment.
- Insertion into the Membrane: The cationic (positively charged) nature of cathelicidins allows them to interact with the negatively charged components of the microbial membranes, such as phospholipids. This interaction allows the peptide to insert itself into the membrane.
- Pore Formation: Once inserted, cathelicidins can form pores or channels in the microbial membrane. This disrupts the integrity of the membrane, leading to leakage of cellular contents, such as ions, proteins, and other essential molecules. This ultimately results in cell death.
- Membrane Disintegration: In some cases, the peptides can physically destabilize the membrane to the point of rupture.

Example:

- LL-37 is able to form pores in the membranes of both Gram-positive and Gram-negative bacteria, as well as in fungal and viral membranes. This disruption is usually not selective, meaning it harms both the pathogen and the pathogen's membrane.

6.2 INHIBITION OF BACTERIAL BIOFILMS

Many bacteria form biofilms, which are protective layers that help them survive in hostile environments (e.g., on medical devices, tissues, and wounds). Biofilms make bacterial infections more difficult to treat because they shield bacteria from both the host immune system and antibiotics.

6.3 CATHELICIDINS AND BIOFILM DISRUPTION

- Cathelicidins, including LL-37, can disrupt or dissolve biofilms, allowing the immune system and antibiotics to target the bacteria more effectively.
- LL-37 works by interacting with the extracellular matrix of the biofilm, which is composed of polysaccharides, proteins, and other biomolecules. By disrupting this matrix, LL-37 weakens the biofilm’s structure and facilitates the elimination of bacteria.
- Pathogen Eradication: LL-37 may help remove biofilm-encased pathogens, making them more susceptible to immune recognition and clearance.

6.4 HCAP-18 PRECURSOR PROTEIN

hCAP-18 is synthesized as an inactive precursor in various cells, including neutrophils, keratinocytes, and mucosal epithelial cells. The full-length protein contains both a cathelin domain (which remains largely inactive) and the LL-37 peptide at the C-terminal.

6.5 PROTEOLYTIC PROCESSING TO LL-37

After hCAP-18 is synthesized, it undergoes enzymatic cleavage by proteinase 3, an enzyme present in neutrophils. This proteolytic cleavage removes the cathelin domain, resulting in the liberation of LL-37, a 37-amino acid peptide. The active peptide retains antimicrobial and immunomodulatory functions, with its effectiveness determined by its amphipathic nature, enabling it to interact with microbial membranes and immune cells.

7. BIOLOGICAL FUNCTIONS OF LL-37

LL-37 is a multifunctional peptide that plays significant roles in defense against pathogens, immune regulation, and tissue repair. The following sections explore these functions in detail:

7.1 ANTIMICROBIAL PROPERTIES OF LL-37

One of the key functions of LL-37 is its ability to directly combat infections caused by various pathogens, including bacteria, fungi, viruses, and parasites. LL-37 has been shown to exert its antimicrobial effects through several mechanisms:

- Membrane Disruption: LL-37 is amphipathic, meaning it contains both hydrophobic and hydrophilic regions. This property allows it to insert into microbial membranes, disrupting their integrity and leading to leakage of cellular contents, thereby killing the pathogen.
- Binding to Lipopolysaccharides (LPS): LL-37 can bind to LPS on the outer membranes of Gram-negative bacteria, neutralizing the toxicity of bacterial endotoxins and preventing infection.
- Direct Inhibition of Viruses: LL-37 has been shown to have antiviral activity against viruses such as influenza and HIV by interfering with viral entry into host cells.

7.2 IMMUNOMODULATION

Beyond its antimicrobial activity, LL-37 plays an important role in modulating the immune system:

- Activation of Immune Cells: LL-37 is involved in the recruitment of immune cells such as neutrophils, monocytes, and dendritic cells to sites of infection. It does this by binding to
- formyl peptide receptors (FPRs) on these cells, triggering chemotaxis and promoting inflammation.
- Cytokine Modulation: LL-37 can influence cytokine production by immune cells. In some contexts, it promotes the release of pro-inflammatory cytokines, while in others, it dampens excessive inflammation by inducing the release of anti-inflammatory cytokines like IL-10.
- Regulation of Adaptive Immunity: LL-37 also influences the adaptive immune response by enhancing T cell activation and antigen presentation. This cross-talk between innate and adaptive immunity enhances the overall immune response to pathogens.

7.3 WOUND HEALING AND TISSUE REPAIR

LL-37 contributes to tissue homeostasis and repair processes:

- Cell Migration and Proliferation: LL-37 has been shown to stimulate the migration and proliferation of keratinocytes and fibroblasts, essential for the wound healing process.
- Angiogenesis: LL-37 promotes the formation of new blood vessels by stimulating vascular endothelial growth factor (VEGF) production. This helps to restore blood supply to injured tissues.
- Barrier Function: LL-37 helps maintain the integrity of epithelial barriers in the skin and mucosal tissues, providing an added layer of protection against infections.

7.4 IMMUNE CELL RECRUITMENT

- Chemoattractant: Cathelicidins act as chemoattractants, signaling immune cells such as neutrophils, monocytes, and macrophages to migrate to the site of infection. This is important for inflammatory responses and initiating the defense against pathogens.
- LL-37 has been shown to attract immune cells by interacting with receptors on these cells, including formyl peptide receptors (FPRs).

7.5 INFLAMMATORY MODULATION

- Cathelicidins like LL-37 can regulate the production of pro-inflammatory cytokines (e.g., TNF-α, IL-1, IL-6) and anti-inflammatory cytokines (e.g., IL-10). This modulation helps maintain a balanced immune response, promoting defense while preventing excessive inflammation that could lead to tissue damage.
- In some cases, cathelicidins help resolve inflammation by promoting the switching off of inflammatory signals after the pathogen is cleared.

7.6 ENHANCING WOUND HEALING AND TISSUE REPAIR

Cathelicidins, including LL-37, are involved in wound healing by promoting processes such as cell migration, proliferation, and angiogenesis (formation of new

blood vessels). This makes them essential for repairing damaged tissues and recovering from infections.

7.7 WOUND HEALING MECHANISMS

- Keratinocyte Migration and Proliferation: LL-37 stimulates the migration of keratinocytes (skin cells) to the wound site, which is essential for the re-epithelialization of the skin after injury.
- Collagen Production: LL-37 enhances collagen synthesis, an important structural protein needed for wound closure and tissue regeneration.
- Angiogenesis: LL-37 has been shown to promote the formation of new blood vessels, improving the supply of oxygen and nutrients to the wound site.

7.8 IMMUNE CELL RECRUITMENT IN WOUND HEALING

- LL-37 also helps recruit immune cells that are necessary for tissue repair and pathogen clearance at the wound site.

7.9 DIRECT ANTIVIRAL ACTIVITY

While cathelicidins are more commonly associated with bacterial and fungal defense, they also show antiviral activity. LL-37, in particular, has been shown to exhibit activity against several types of viruses.

7.9.1 MECHANISM OF ACTION IN VIRAL INFECTIONS

- Direct Membrane Disruption: LL-37 can directly interact with viral lipid bilayers and disrupt their structure, preventing the virus from entering host cells.
- Immune Modulation in Viral Infections: Cathelicidins can also modulate the immune response during viral infections, helping to clear the virus while controlling inflammation.

7.9.2 OTHER MECHANISMS

- Binding to Endotoxins: Cathelicidins like LL-37 can bind to endotoxins (toxic substances released by bacteria) and neutralize their harmful effects. This can help prevent sepsis and systemic inflammation.
- Anticancer Effects: Some research has shown that LL-37 may have anticancer properties by promoting immune responses against tumors and inhibiting tumor growth.

10. CLINICAL IMPLICATIONS AND THERAPEUTIC POTENTIAL OF LL-37

Given its broad range of functions, LL-37 holds significant promise for therapeutic use. The following sections highlight its potential in clinical applications:

10.1 ANTIMICROBIAL RESISTANCE

LL-37's broad-spectrum antimicrobial properties make it a potential alternative to traditional antibiotics, particularly as antimicrobial resistance (AMR) continues to rise. LL-37 is effective against both Gram-positive and Gram-negative bacteria, as well as multidrug-resistant strains, providing a potential solution to resistant infections.

10.2 AUTOIMMUNE DISEASES

In autoimmune diseases, the immune system mistakenly attacks healthy tissues. LL-37 has been implicated in the pathogenesis of conditions like systemic lupus erythematosus (SLE), where its overexpression can contribute to chronic inflammation and tissue damage. Conversely, its ability to modulate immune responses suggests it could be harnessed for therapeutic use in inflammatory and autoimmune diseases.

11. WOUND HEALING AND TISSUE REGENERATION

LL-37 has shown promise in accelerating wound healing, particularly in chronic wounds such as diabetic ulcers and burns. Its ability to stimulate cell migration, angiogenesis, and barrier function makes it a potential candidate for promoting tissue repair and regeneration in clinical settings.

CANCER IMMUNOTHERAPY

LL-37's ability to influence immune responses has led to exploration in cancer immunotherapy. Some studies suggest that LL-37 can promote anti-tumor immunity by enhancing the infiltration of immune cells into tumors. Its role in modulating immune responses could be leveraged to improve the effectiveness of cancer treatments.



FIGURE 2
Mechanisms underlaying the therapeutic efficacy of cathelicidins/Nanoparticles. (A) Bacteria. 1—Membrane disruption, 2—Membrane translocation, 3—DNA/RNA synthesis, 4—Protein synthesis/folding, 5—Inhibition of peptidoglycan biosynthesis, 6—Alteration in cell shape. IM, Inner membrane. (B) Antiviral action. 1—Envelope disruption, 2—Inhibition of viral attachment/fusion/entry, 3—Down regulation of host receptors, 4—Down regulation of inflammatory cytokines, 5—Increased resistance to apoptosis by upregulation of HSP60. (C) Immunomodulatory /autoimmune diseases. 1—Increased mucus production, 2—Gut microbiota homeostasis, 3—Angiogenesis, 4—Reepithelization/wound healing, 5—Increased expression of IL-10, 6—Inhibition of pro-inflammatory cytokines, 7—Inhibition of TLR4 pathway, 8—Reduction in nitric oxide (NO) production, 9—Promotion of cell differentiation to anti-inflammatory phenotype, 10—Inhibition of cell trafficking. (D) Cancer treatment. 1—Inhibition of tumor cell proliferation, 2—Induction of apoptosis/necrosis, 3—Down regulation of VEGF, 4—Upregulation of TNF-α and IFN-γ, 5—Angiogenesis inhibition.

Fig 3:Therapeutic efficacy in cathelicidin

LL-37 IN DISEASE STATE

A deficiency in LL-37 can result in increased susceptibility to infections and impaired wound healing. Patients with cystic fibrosis and chronic obstructive pulmonary disease (COPD) have shown lower levels of LL-37, making them more vulnerable to pulmonary infections.

11.1 OVEREXPRESSION OF LL-37

Excessive LL-37 expression can lead to chronic inflammation and autoimmune disease. In conditions such as psoriasis and rheumatoid arthritis, elevated LL-37 levels exacerbate tissue damage and promote inflammatory responses.

11.2 FUTURE DIRECTIONS AND CHALLENGES

Delivery Mechanisms: Effective delivery of LL-37 to infection sites or tissues requiring repair remains a challenge. Nanotechnology-based drug delivery systems may enhance its stability and targeting.Regulation of Immune Responses: Since LL-37 has both pro- and anti-inflammatory properties, its use in autoimmune diseases requires careful modulation to avoid exacerbating inflammation.

12. RESEARCH DIRECTIONS

Future studies should focus on understanding the precise mechanisms of LL-37's immune modulation, optimizing its antimicrobial efficacy, and exploring its use in combination with other therapeutic agents, such as antibiotics or immunomodulators.

LL-37's diverse functions make it a subject of intense medical research. Its role in infection control, wound healing, and immune regulation has led to potential therapeutic applications:

- Antibiotic Resistance: LL-37's broad-spectrum antimicrobial properties make it a promising candidate for treating drug-resistant infections, such as those caused by multi-drug resistant bacteria like *MRSA* (methicillin-resistant *Staphylococcus aureus*).
- Wound Healing and Burn Treatment: Given its ability to promote tissue repair and its antimicrobial effects, LL-37 is being studied for topical applications to treat chronic wounds, burns, and ulcers.
- Cancer: LL-37's role in immune surveillance and its potential to regulate tumor growth is under investigation. Some studies suggest that LL-37 could have antitumor effects, while others are exploring its potential as a targeted therapy for cancer cells.
- Inflammatory Diseases: Because LL-37 modulates inflammation, it may have therapeutic potential in treating autoimmune conditions, such as psoriasis and rheumatoid arthritis, where immune dysregulation occurs.

13. CONCLUSION

LL-37 is a versatile peptide with significant implications for both basic immunology and clinical medicine. Its broad-spectrum antimicrobial activity, combined with its ability to modulate immune responses and promote tissue repair, makes it an exciting therapeutic candidate. Continued research into LL-37's mechanisms and its clinical applications could pave the way for novel treatments for infections, autoimmune diseases, and chronic wounds.Peptides are an essential part of biology and medicine. Their roles in hormonal regulation, immune function, neurotransmission, muscle growth, and skin health make them critical to maintaining homeostasis and overall bodily function. The research and application of peptides in pharmaceuticals and biotechnology hold significant promise, especially in the development of targeted treatments for diseases and enhancing human health LL-37 is a critical antimicrobial peptide derived from the larger hCAP-18 precursor. Its structure, function, and derivation are intricately tied to its roles in immune defense, wound healing, and infection control. While it holds great promise in medical research and treatment development, the balance of its inflammatory effects must be carefully considered in therapeutic applications. With ongoing research, LL-37 could play an increasingly important role in combating infections and enhancing the healing of chronic wounds, among other therapeutic uses.

ACKNOWLEDGEMENT

The authors are grateful to thank SRM College of Pharmacy, SRM Institute of Science and Technology, Kattankulathur, to prove the required facility and support out this research work

REFERENCE

[1] Kahlenberg, J. M., et al. *Little Peptide, Big Effects: The Role of LL-37 in Inflammation and Autoimmune Disease. J. Immunol.* 191(10): 4895–4901 (2013).

[2] Guerra, M. E. S., Vieira, B., Calazans, A. P. C. T., Destro, G. V., Melo, K., Rodrigues, E., Waz, N. T., Girardello, R., Darrieux, M., & Converso, T. R. *Expression and secretion of cathelicidin antimicrobial peptides in murine mammary glands and human milk. Infect. Immun.* 91(2): e00568-22 (2023).

[3] Schneider, D. J. *LL-37: A Direct Link Between Inflammation and Myocardial Infarction. Am. J. Physiol. Heart Circ. Physiol.* 303(12): H1443–H1445 (2012).

[4] Hu, Z., Murakami, T., Suzuki, K., Tamura, H., Kuwahara-Arai, K., Iba, T., & Nagaoka, I. *Antimicrobial Cathelicidin Peptide LL-37 Inhibits the LPS/ATP-Induced Pyroptosis of Macrophages by Dual Mechanism. Int. J. Mol. Sci.* 17(5): 636 (2016).

[5] Levy, S. B. & Marshall, B. Antibacterial resistance worldwide: causes, challenges and responses. *Nat. Med.* 10(12 Suppl): S122–S129 (2004).

[6] Peschel, A. & Sahl, H.-G. The co-evolution of host cationic antimicrobial peptides and microbial resistance. *Nat. Rev. Microbiol.* 4(7): 529–536 (2006).

[7] Zasloff, M. Antimicrobial peptides of multicellular organisms. *Nature* 415(6870): 389–395 (2002).

[8] Ganz, T. Defensins: antimicrobial peptides of innate immunity. *Nat. Rev. Immunol.* 3(9): 710–720 (2003).

[9] Fjell, C. D., Hiss, J. A., Hancock, R. E. W. & Schneider, G. Designing antimicrobial peptides: form follows function. *Nat. Rev. Drug Discov.* 11(1): 37–51 (2012).

[10] Fox, J. L. Antimicrobial peptides stage a comeback. *Nat. Biotechnol.* 31(5): 379–382 (2013).

[11] Seminario, A. L., Karczewski, A. E., Chung, W., Wang, Y., Wamalwa, D., Benki-Nugent, S., John-Stewart, G., & Slyker, J. A. *Salivary Cathelicidin (LL-37) in Children and Adolescents Living with HIV*. *Biomedicine Hub* 9(1): 25–30 (2024).

[12] Koo, H. B. & Seo, J. Antimicrobial peptides under clinical investigation. *Pept. Sci.* 111(5): e24122 (2019).

[13] Zeth, K. & Sancho-Vaello, E. The human antimicrobial peptides dermcidin and LL-37 show novel distinct pathways in membrane interactions. *Front. Chem.* 5: 86 (2017).

[14] Vandamme, D., Landuyt, B., Luyten, W. & Schoofs, L. A comprehensive summary of LL-37, the factotum human cathelicidin peptide. *Cell. Immunol.* 280(1): 22–35 (2012).

[15] Savini, F. et al. Cell-density dependence of host-defense peptide activity and selectivity in the presence of host cells. *ACS Chem. Biol.* 12(1): 52–56 (2017).

[16] Wilson, D. N., Guichard, G. & Innis, C. A. Antimicrobial peptides target ribosomes. *Oncotarget* 6(19): 16826–16827 (2015).

[17] Krizsan, A. et al. Insect-derived proline-rich antimicrobial peptides kill bacteria by inhibiting bacterial protein translation at the 70S ribosome. *Angew. Chem. Int. Ed. Engl.* 53(49): 12236–12239 (2014).

[18] Mardirossian, M. et al. The dolphin proline-rich antimicrobial peptide Tur1A inhibits protein synthesis by targeting the bacterial ribosome. *Cell Chem. Biol.* 25(5): 530–539.e7 (2018).

[19] Roy, R. N., Lomakin, I. B., Gagnon, M. G. & Steitz, T. A. The mechanism of inhibition of protein synthesis by the proline-rich peptide oncocin. *Nat. Struct. Mol. Biol.* 22(7): 466–469 (2015).

[20] Seefeldt, A. C. et al. The proline-rich antimicrobial peptide Onc112 inhibits translation by blocking and destabilizing the initiation complex. *Nat. Struct. Mol. Biol.* 22(6): 470–475 (2015).

[21] Shahmiri, M. et al. Membrane core-specific antimicrobial action of cathelicidin LL-37 peptide switches between pore and nanofibre formation. *Sci. Rep.* 6: 38184 (2016).

[22] Schneider, D. J. LL-37: A direct link between inflammation and myocardial infarction. *Am. J. Physiol. Heart Circ. Physiol.* 303(12): H1443–H1445 (2012).

[23] Hu, Z. et al. Antimicrobial cathelicidin peptide LL-37 inhibits the LPS/ATP-induced pyroptosis of macrophages by dual mechanism. *Int. J. Mol. Sci.* 17(5): 636 (2016).

[24] Wnorowska, U. et al. Nanoantibiotics containing membrane-active human cathelicidin LL-37 or synthetic ceragenins attached to the surface of magnetic nanoparticles: current status and potential future applications. *J. Nanobiotechnology* 18: 3 (2020).

[25] Yang, B. et al. Significance of LL-37 on immunomodulation and disease outcome. *Front. Immunol.* 11: 544129 (2020).

[26] Hu, Z., Murakami, T., Suzuki, K., Tamura, H., Kuwahara-Arai, K., Iba, T. & Nagaoka, I. Antimicrobial cathelicidin peptide LL-37 inhibits the LPS/ATP-induced pyroptosis of macrophages by dual mechanism. *Int. J. Mol. Sci.* 17(5): 636 (2016).

[27] Eduarda Souza Guerra, M. et al. Expression and secretion of cathelicidin antimicrobial peptides in murine mammary glands and human milk. *J. Immunol.* 177(9): 6087–6096 (2006).

[28] Febriza, A., Hatta, M., Natzir, R., Kasim, V. N. A., & Idrus, H. H. Activity of antimicrobial peptide cathelicidin on bacterial infection. *J. Infect. Dev. Ctries.* 12(9): 774–780 (2018).

[29] Mithal, A. et al. Global Vitamin D status and determinants of hypovitaminosis D. *Osteoporos. Int.* 20(11): 1807–1820 (2009).

[30] Van Schoor, N. M. & Lips, P. Worldwide Vitamin D status. *Best Pract. Res. Clin. Endocrinol. Metab.* 25(4): 671–680 (2011).

[31] Aparna, P., Muthathal, S., Nongkynrih, B. & Gupta, S. K. Vitamin D deficiency in India. *J. Family Med. Prim. Care* 7(2): 324–330 (2018).

[32] Savini, F. et al. Host defense peptides and their potential use as therapeutic agents. *Curr. Pharm. Des.* 23(27): 4114–4131 (2017).

[33] Mahlapuu, M. et al. Antimicrobial peptides: An emerging category of therapeutic agents. *Front. Cell. Infect. Microbiol.* 6: 194 (2016).

[34] Bhattacharjya, S., Zhang, Z., & Ramamoorthy, A. *LL-37: Structures, Antimicrobial Activity, and Influence on Amyloid-Related Diseases. Biomolecules* 14(3): 320 (2024).